1. Home
  2. KLC vs AGIO Comparison

KLC vs AGIO Comparison

Compare KLC & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KLC
  • AGIO
  • Stock Information
  • Founded
  • KLC 1969
  • AGIO 2007
  • Country
  • KLC United States
  • AGIO United States
  • Employees
  • KLC N/A
  • AGIO N/A
  • Industry
  • KLC
  • AGIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • KLC
  • AGIO Health Care
  • Exchange
  • KLC NYSE
  • AGIO Nasdaq
  • Market Cap
  • KLC 1.5B
  • AGIO 1.4B
  • IPO Year
  • KLC 2024
  • AGIO 2013
  • Fundamental
  • Price
  • KLC $9.64
  • AGIO $34.29
  • Analyst Decision
  • KLC Buy
  • AGIO Buy
  • Analyst Count
  • KLC 8
  • AGIO 6
  • Target Price
  • KLC $25.50
  • AGIO $58.60
  • AVG Volume (30 Days)
  • KLC 586.5K
  • AGIO 593.4K
  • Earning Date
  • KLC 08-14-2025
  • AGIO 07-31-2025
  • Dividend Yield
  • KLC N/A
  • AGIO N/A
  • EPS Growth
  • KLC N/A
  • AGIO N/A
  • EPS
  • KLC N/A
  • AGIO 11.45
  • Revenue
  • KLC $2,676,609,000.00
  • AGIO $37,035,000.00
  • Revenue This Year
  • KLC $5.52
  • AGIO $22.30
  • Revenue Next Year
  • KLC $3.95
  • AGIO $220.58
  • P/E Ratio
  • KLC N/A
  • AGIO $3.10
  • Revenue Growth
  • KLC 5.75
  • AGIO 25.96
  • 52 Week Low
  • KLC $9.79
  • AGIO $23.42
  • 52 Week High
  • KLC $29.89
  • AGIO $62.58
  • Technical
  • Relative Strength Index (RSI)
  • KLC N/A
  • AGIO 64.77
  • Support Level
  • KLC N/A
  • AGIO $34.49
  • Resistance Level
  • KLC N/A
  • AGIO $35.82
  • Average True Range (ATR)
  • KLC 0.00
  • AGIO 1.29
  • MACD
  • KLC 0.00
  • AGIO 0.08
  • Stochastic Oscillator
  • KLC 0.00
  • AGIO 70.98

About KLC KINDERCARE LEARNING COMPANIES INC

KinderCare Learning Companies Inc is a private provider of early childhood education and care services (ECE) in the United States. It serves children ranging from 6 weeks to 12 years of age across its market footprint of around 1,480 early childhood education centers with a capacity of more than 194,000 children and contracts for more than 650 before- and after-school sites located in 40 states and the District of Columbia. Its segment derives revenue from providing early childhood education and care services at centers and before- and after-school sites.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: